The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review

Christina Greenaway¹,², Manish Pareek³, Claire-Nour Abou Chakra⁴, Moneeza Walji², Iuliia Makarenko², Balqis Alabdulkarim², Catherine Hogan¹,², Ted McConnell², Brittany Scarfo², Robin Christensen⁵,⁶, Anh Tran⁷, Nick Rowbotham⁷, Marieke J van der Werf⁸, Teymur Noori⁸, Kevin Pottie⁹, Alberto Matteelli¹⁰, Dominik Zenner¹¹,¹², Rachael L. Morton⁷

Affiliations:
¹ Division of Infectious Diseases, Jewish General Hospital, McGill University, Montreal, Canada
² Centre for Clinical Epidemiology of the Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada
³ Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom
⁴ Division of Infectious Diseases, Sherbrooke, Canada
⁵ Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
⁶ Department of Rheumatology, Odense University Hospital, Denmark
⁷ National Health and Medical Research Council, NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia
⁸ European Centre for Disease Prevention and Control, Stockholm, Sweden
⁹ Bruyere Research Institute, University of Ottawa, Ottawa, Ontario, Canada
¹⁰ Clinic of Infectious and Tropical Diseases, University of Brescia and Brescia Spedali Civili General Hospital, World Health Organization Collaborating Centre for TB/HIV and TB Elimination, Brescia, Italy
¹¹ Respiratory Diseases Department, Centre for Infectious Disease Surveillance and Control (CIDSC), Public Health England, London, United Kingdom
¹² Department of Infection and Population Health, University College London, London, United Kingdom

Correspondence: Christina Greenaway (ca.greenaway@mcgill.ca)


Received: ; Accepted: ;

Abstract

Background
Migrants account for a large and growing proportion of tuberculosis (TB) cases in low-incidence countries in the European Union/European Economic Area (EU/EEA) which are primarily due to reactivation of latent TB infection (LTBI). Addressing LTBI among migrants will be critical to achieve TB elimination. Methods: We conducted a systematic review to determine effectiveness (performance of diagnostic tests, efficacy of treatment, uptake and completion of screening and
treatment) and a second systematic review on cost-effectiveness of LTBI screening programmes for migrants living in the EU/EEA. **Results:** We identified seven systematic reviews and 16 individual studies that addressed our aims. Tuberculin skin tests and interferon gamma release assays had high sensitivity (79%) but when positive, both tests poorly predicted the development of active TB (incidence rate ratio: 2.07 and 2.40, respectively). Different LTBI treatment regimens had low to moderate efficacy but were equivalent in preventing active TB. Rifampicin-based regimens may be preferred because of lower hepatotoxicity (risk ratio = 0.15) and higher completion rates (82% vs 69%) compared with isoniazid. Only 14.3% of migrants eligible for screening completed treatment because of losses along all steps of the LTBI care cascade. Limited economic analyses suggest that the most cost-effective approach may be targeting young migrants from high TB incidence countries. **Discussion:** The effectiveness of LTBI programmes is limited by the large pool of migrants with LTBI, poorly predictive tests, long treatments and a weak care cascade. Targeted LTBI programmes that ensure high screening uptake and treatment completion will have greatest individual and public health benefit.

© This work is licensed under a Creative Commons Attribution 4.0 International License.

Comment has been disabled for this content